Industrial Complex

In a property of about 151 thousand m² with 48.9 thousand m² of built-up area in the city of Embu das Artes, our industrial complex is scenery for the present and the future. Present due to productive and development structure we already have there. Future because this complex is where we generate innovation and where, as of 2016, we will initiate the production of biological medications. This is an important milestone for our company and for Brazil and it is, above all, another expression of our commitment to people’s lives.

In our units, attention is present in every detail. Our good manufacturing practices are ate sted by very significant certifications, both national and international, which allow us to export pharmaceutical ingredients and medications to several countries in Europe, Asia and Latin America. From environmental perspective, we have an Environmental Management System certified by ISO 14001.

Integrated Development Center (IDC)
In this modern laboratory complex, we conduct our researches of new medications and new routes for synthesis of drug substances. For that, we combine a robust structure of analytical resources with the competence of a cross functional team, comprised of chemists and pharmacists, among which are masters and doctors. In this research and development site, we plant the innovations that will feed the portfolio of products manufactured in our Pharmaceutical and Pharmacochemical Units. Each year, we apply at least 10% of our income to Research & Development (R&D) – an expressive investment that, above all, translates how we want to grow: reaching more and more patients and contributing to make a difference in their lives.
Pharmacochemical Unit
This was our first unit set up in Embu das Artes, in São Paulo. And, in the 1990s, when many industries in Brazil chose to stop producing Active Pharmaceutical Ingredients (APIs) before the challenges of marketing opening, we followed the opposite path. We believed that the verticalization would guarantee important differentials for us. And time proved us right. By producing our raw material, we know the nature of our drugs in depth, we can anticipate releases, we have control over the productive process from early steps and we depend less on foreign suppliers. Furthermore, we gather assets that allow us to take part in partnerships with the public sector for the development of new products, such as the one that resulted in the release and production of Tacrolimus, an immunosuppressant for the prevention of transplanted organs rejection.
Pharmaceutical Unit
Here, we produce the medications of all our lines. Currently, we have about 80 brands and 170 forms. Thanks to our constant investments in equipment, our unit counts on cutting-edge technologic resources added to a strict quality assurance and control. Every year, we produce more than 50 million medication units.

Libbs - Porque se trata da vida

Who whe are

A company inspired by life

Our Products

Future

Your health

Join us

Contact us

About
us